Disease Control Achieved Using Atezolizumab + Bevacizumab in a Patient With Sarcomatoid Hepatocellular Carcinoma (SHCC), a Rare Variant Excluded From the IMbrave150 Trial

Maria G Fencer; Catherine H Davis; Jieqi Liu; Mark A Galan; Kristen R Spencer

doi:10.1177/23247096221129470

Disease Control Achieved Using Atezolizumab + Bevacizumab in a Patient With Sarcomatoid Hepatocellular Carcinoma (SHCC), a Rare Variant Excluded From the IMbrave150 Trial

J Investig Med High Impact Case Rep. 2022 Jan-Dec:10:23247096221129470. doi: 10.1177/23247096221129470.

Authors

Maria G Fencer^{1

2}, Catherine H Davis^{1

3}, Jieqi Liu³, Mark A Galan², Kristen R Spencer³

Affiliations

¹ Rutgers Robert Wood Johnson University Medical School, New Brunswick, NJ, USA.
² Rutgers New Jersey Medical School, Newark, USA.
³ Rutgers Cancer Institute of New Jersey, New Brunswick, USA.

Abstract

Sarcomatoid hepatocellular carcinoma (SHCC) is a rare variant of liver cancer that lacks treatment options. The IMbrave trail demonstrated the efficacy of atezolizumab and bevacizumab (A + B) in patients with unresectable hepatocellular carcinoma but excluded patients with sarcomatoid variants. Herein, we describe a case of disease control achieved using the IMbrave regimen in a patient with sarcomatoid hepatocellular carcinoma.

Keywords: atezolizumab; bevacizumab; hepatocellular carcinoma; sarcomatoid.

Publication types

Case Reports

MeSH terms

Antibodies, Monoclonal, Humanized / therapeutic use
Bevacizumab / therapeutic use
Carcinoma, Hepatocellular* / drug therapy
Humans
Liver Neoplasms* / drug therapy

Substances

Bevacizumab
atezolizumab
Antibodies, Monoclonal, Humanized